Nucleai

Nucleai, headquartered in Tel Aviv, provides an AI-powered spatial tissue analysis platform for oncology drug development. It integrates multimodal tissue imaging (H&E, immunohistochemistry, multiplex immunofluorescence and spatial transcriptomics) with clinical outcome data to derive explainable spatial biomarkers. The company reports work with more than 12 of the top 20 biopharma companies across 30 or more clinical trials, and holds ISO 27001 and ISO 13485 certification. Recent collaborations include a large-scale antibody-drug conjugate (ADC) programme with Gilead Sciences examining why target-positive tumours resist ADCs (2026), an integrated spatial proteomics offering with Sirona Dx and an expanded partnership with the University of Glasgow. Investors named on the website include Section32, Sanofi, M Ventures and Debiopharm; no financing round is disclosed.